Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Aminoguanidine Hydrazone Derivatives as Nonpeptide NPFF1 Receptor Antagonists Reverse Opioid Induced Hyperalgesia.

Hammoud H, Elhabazi K, Quillet R, Bertin I, Utard V, Laboureyras E, Bourguignon JJ, Bihel F, Simonnet G, Simonin F, Schmitt M.

ACS Chem Neurosci. 2018 Nov 21;9(11):2599-2609. doi: 10.1021/acschemneuro.8b00099. Epub 2018 May 16.

PMID:
29727163
2.

A bifunctional-biased mu-opioid agonist-neuropeptide FF receptor antagonist as analgesic with improved acute and chronic side effects.

Drieu la Rochelle A, Guillemyn K, Dumitrascuta M, Martin C, Utard V, Quillet R, Schneider S, Daubeuf F, Willemse T, Mampuys P, Maes BUW, Frossard N, Bihel F, Spetea M, Simonin F, Ballet S.

Pain. 2018 Sep;159(9):1705-1718. doi: 10.1097/j.pain.0000000000001262.

PMID:
29708942
3.

[The neuropeptide FF: a signal for M1 to M2 type switching in macrophages from the adipose tissue].

Quillet R, Simonin F.

Med Sci (Paris). 2018 Jan;34(1):27-29. doi: 10.1051/medsci/20183401008. Epub 2018 Jan 31. French. No abstract available.

4.

Morphine-induced hyperalgesia involves mu opioid receptors and the metabolite morphine-3-glucuronide.

Roeckel LA, Utard V, Reiss D, Mouheiche J, Maurin H, Robé A, Audouard E, Wood JN, Goumon Y, Simonin F, Gaveriaux-Ruff C.

Sci Rep. 2017 Sep 4;7(1):10406. doi: 10.1038/s41598-017-11120-4.

5.

Neuropeptide FF increases M2 activation and self-renewal of adipose tissue macrophages.

Waqas SFH, Hoang AC, Lin YT, Ampem G, Azegrouz H, Balogh L, Thuróczy J, Chen JC, Gerling IC, Nam S, Lim JS, Martinez-Ibañez J, Real JT, Paschke S, Quillet R, Ayachi S, Simonin F, Schneider EM, Brinkman JA, Lamming DW, Seroogy CM, Röszer T.

J Clin Invest. 2017 Sep 1;127(9):3559. doi: 10.1172/JCI95841. Epub 2017 Jul 31. No abstract available.

6.

Neuropeptide FF increases M2 activation and self-renewal of adipose tissue macrophages.

Waqas SFH, Hoang AC, Lin YT, Ampem G, Azegrouz H, Balogh L, Thuróczy J, Chen JC, Gerling IC, Nam S, Lim JS, Martinez-Ibañez J, Real JT, Paschke S, Quillet R, Ayachi S, Simonin F, Schneider EM, Brinkman JA, Lamming DW, Seroogy CM, Röszer T.

J Clin Invest. 2017 Jun 30;127(7):2842-2854. doi: 10.1172/JCI90152. Epub 2017 Jun 5. Erratum in: J Clin Invest. 2017 Sep 1;127(9):3559.

7.

RF313, an orally bioavailable neuropeptide FF receptor antagonist, opposes effects of RF-amide-related peptide-3 and opioid-induced hyperalgesia in rodents.

Elhabazi K, Humbert JP, Bertin I, Quillet R, Utard V, Schneider S, Schmitt M, Bourguignon JJ, Laboureyras E, Ben Boujema M, Simonnet G, Ancel C, Simonneaux V, Beltramo M, Bucher B, Sorg T, Meziane H, Schneider E, Petit-Demoulière B, Ilien B, Bihel F, Simonin F.

Neuropharmacology. 2017 May 15;118:188-198. doi: 10.1016/j.neuropharm.2017.03.012. Epub 2017 Mar 10.

PMID:
28288815
8.

Opioid-induced hyperalgesia: Cellular and molecular mechanisms.

Roeckel LA, Le Coz GM, Gavériaux-Ruff C, Simonin F.

Neuroscience. 2016 Dec 3;338:160-182. doi: 10.1016/j.neuroscience.2016.06.029. Epub 2016 Jun 23. Review.

PMID:
27346146
9.

Development of Dipeptidic hGPR54 Agonists.

Doebelin C, Bertin I, Schneider S, Schmitt M, Bourguignon JJ, Ancel C, Simonneaux V, Simonin F, Bihel F.

ChemMedChem. 2016 Oct 6;11(19):2147-2154. doi: 10.1002/cmdc.201600331. Epub 2016 Aug 26.

PMID:
27562608
10.

Bifunctional Peptide-Based Opioid Agonist-Nociceptin Antagonist Ligands for Dual Treatment of Acute and Neuropathic Pain.

Guillemyn K, Starnowska J, Lagard C, Dyniewicz J, Rojewska E, Mika J, Chung NN, Utard V, Kosson P, Lipkowski AW, Chevillard L, Arranz-Gibert P, Teixidó M, Megarbane B, Tourwé D, Simonin F, Przewlocka B, Schiller PW, Ballet S.

J Med Chem. 2016 Apr 28;59(8):3777-92. doi: 10.1021/acs.jmedchem.5b01976. Epub 2016 Apr 14.

11.

RF-amide neuropeptides and their receptors in Mammals: Pharmacological properties, drug development and main physiological functions.

Quillet R, Ayachi S, Bihel F, Elhabazi K, Ilien B, Simonin F.

Pharmacol Ther. 2016 Apr;160:84-132. doi: 10.1016/j.pharmthera.2016.02.005. Epub 2016 Feb 17. Review.

PMID:
26896564
12.

The effect of neuropeptide FF in the amygdala kindling model.

Buffel I, Meurs A, Portelli J, Raedt R, De Herdt V, Poppe L, De Meulenaere V, Wadman W, Bihel F, Schmitt M, Vonck K, Bourguignon JJ, Simonin F, Smolders I, Boon P.

Acta Neurol Scand. 2016 Sep;134(3):181-8. doi: 10.1111/ane.12526. Epub 2015 Oct 27.

PMID:
26503695
13.

Effects of systematic N-terminus deletions and benzoylations of endogenous RF-amide peptides on NPFF1R, NPFF2R, GPR10, GPR54 and GPR103.

Rouméas L, Humbert JP, Schneider S, Doebelin C, Bertin I, Schmitt M, Bourguignon JJ, Simonin F, Bihel F.

Peptides. 2015 Sep;71:156-61. doi: 10.1016/j.peptides.2015.07.016. Epub 2015 Jul 23.

PMID:
26211894
14.

Rapid and scalable synthesis of innovative unnatural α,β or γ-amino acids functionalized with tertiary amines on their side-chains.

Schneider S, Ftouni H, Niu S, Schmitt M, Simonin F, Bihel F.

Org Biomol Chem. 2015 Jul 7;13(25):7020-6. doi: 10.1039/c5ob00828j. Epub 2015 Jun 1.

PMID:
26030164
15.

Neuropeptide FF receptors as novel targets for limbic seizure attenuation.

Portelli J, Meurs A, Bihel F, Hammoud H, Schmitt M, De Kock J, Utard V, Humbert JP, Bertin I, Buffel I, Coppens J, Tourwe D, Maes V, De Prins A, Vanhaecke T, Massie A, Balasubramaniam A, Boon P, Bourguignon JJ, Simonin F, Smolders I.

Neuropharmacology. 2015 Aug;95:415-23. doi: 10.1016/j.neuropharm.2015.04.030. Epub 2015 May 9.

PMID:
25963417
16.

Neuropeptide FF and prolactin-releasing peptide decrease cortical excitability through activation of NPFF receptors.

Buffel I, Meurs A, Portelli J, Raedt R, De Herdt V, Sioncke L, Wadman W, Bihel F, Schmitt M, Vonck K, Bourguignon JJ, Simonin F, Smolders I, Boon P.

Epilepsia. 2015 Mar;56(3):489-98. doi: 10.1111/epi.12928. Epub 2015 Feb 12.

17.

Development of a peptidomimetic antagonist of neuropeptide FF receptors for the prevention of opioid-induced hyperalgesia.

Bihel F, Humbert JP, Schneider S, Bertin I, Wagner P, Schmitt M, Laboureyras E, Petit-Demoulière B, Schneider E, Mollereau C, Simonnet G, Simonin F, Bourguignon JJ.

ACS Chem Neurosci. 2015 Mar 18;6(3):438-45. doi: 10.1021/cn500219h. Epub 2015 Feb 7.

PMID:
25588572
18.

Involvement of Mammalian RF-Amide Peptides and Their Receptors in the Modulation of Nociception in Rodents.

Ayachi S, Simonin F.

Front Endocrinol (Lausanne). 2014 Oct 2;5:158. doi: 10.3389/fendo.2014.00158. eCollection 2014. Review.

19.

Assessment of morphine-induced hyperalgesia and analgesic tolerance in mice using thermal and mechanical nociceptive modalities.

Elhabazi K, Ayachi S, Ilien B, Simonin F.

J Vis Exp. 2014 Jul 29;(89):e51264. doi: 10.3791/51264.

20.

Recombinant human melatonin receptor MT1 isolated in mixed detergents shows pharmacology similar to that in mammalian cell membranes.

Logez C, Berger S, Legros C, Banères JL, Cohen W, Delagrange P, Nosjean O, Boutin JA, Ferry G, Simonin F, Wagner R.

PLoS One. 2014 Jun 24;9(6):e100616. doi: 10.1371/journal.pone.0100616. eCollection 2014.

21.

Endogenous mammalian RF-amide peptides, including PrRP, kisspeptin and 26RFa, modulate nociception and morphine analgesia via NPFF receptors.

Elhabazi K, Humbert JP, Bertin I, Schmitt M, Bihel F, Bourguignon JJ, Bucher B, Becker JA, Sorg T, Meziane H, Petit-Demoulière B, Ilien B, Simonin F.

Neuropharmacology. 2013 Dec;75:164-71. doi: 10.1016/j.neuropharm.2013.07.012. Epub 2013 Aug 2.

PMID:
23911743
22.

Identification of a novel protein-protein interaction motif mediating interaction of GPCR-associated sorting proteins with G protein-coupled receptors.

Bornert O, Møller TC, Boeuf J, Candusso MP, Wagner R, Martinez KL, Simonin F.

PLoS One. 2013;8(2):e56336. doi: 10.1371/journal.pone.0056336. Epub 2013 Feb 18.

23.

Development of sub-nanomolar dipeptidic ligands of neuropeptide FF receptors.

Gealageas R, Schneider S, Humbert JP, Bertin I, Schmitt M, Laboureyras E, Dugave C, Mollereau C, Simonnet G, Bourguignon JJ, Simonin F, Bihel F.

Bioorg Med Chem Lett. 2012 Dec 15;22(24):7471-4. doi: 10.1016/j.bmcl.2012.10.049. Epub 2012 Oct 17.

PMID:
23131340
24.

Involvement of neuropeptide FF receptors in neuroadaptive responses to acute and chronic opiate treatments.

Elhabazi K, Trigo JM, Mollereau C, Moulédous L, Zajac JM, Bihel F, Schmitt M, Bourguignon JJ, Meziane H, Petit-demoulière B, Bockel F, Maldonado R, Simonin F.

Br J Pharmacol. 2012 Jan;165(2):424-35. doi: 10.1111/j.1476-5381.2011.01563.x.

25.

Impaired striatum-dependent behavior in GASP-1-knock-out mice.

Mathis C, Bott JB, Candusso MP, Simonin F, Cassel JC.

Genes Brain Behav. 2011 Apr;10(3):299-308. doi: 10.1111/j.1601-183X.2010.00666.x. Epub 2010 Dec 15.

26.

Identification and biological significance of G protein-coupled receptor associated sorting proteins (GASPs).

Abu-Helo A, Simonin F.

Pharmacol Ther. 2010 Jun;126(3):244-50. doi: 10.1016/j.pharmthera.2010.03.004. Epub 2010 Apr 13. Review. Erratum in: Pharmacol Ther. 2011 Oct;132(1):123.

PMID:
20394773
27.

Prolactin-releasing peptide effects in the rat brain are mediated through the Neuropeptide FF receptor.

Ma L, MacTavish D, Simonin F, Bourguignon JJ, Watanabe T, Jhamandas JH.

Eur J Neurosci. 2009 Oct;30(8):1585-93. doi: 10.1111/j.1460-9568.2009.06956.x. Epub 2009 Oct 12.

PMID:
19821834
28.

Attenuated behavioural responses to acute and chronic cocaine in GASP-1-deficient mice.

Boeuf J, Trigo JM, Moreau PH, Lecourtier L, Vogel E, Cassel JC, Mathis C, Klosen P, Maldonado R, Simonin F.

Eur J Neurosci. 2009 Sep;30(5):860-8. doi: 10.1111/j.1460-9568.2009.06865.x. Epub 2009 Aug 27.

PMID:
19712096
29.

Neuropeptide FF and neuropeptide VF inhibit GABAergic neurotransmission in parvocellular neurons of the rat hypothalamic paraventricular nucleus.

Jhamandas JH, Simonin F, Bourguignon JJ, Harris KH.

Am J Physiol Regul Integr Comp Physiol. 2007 May;292(5):R1872-80. Epub 2007 Feb 8.

30.

[RF9, a powerful and selective antagonist of the neuropeptide FF receptors, prevents the development of the tolerance to opioids].

Bourguignon JJ, Simonnet G, Simonin F.

Med Sci (Paris). 2006 Jun-Jul;22(6-7):579-80. French. No abstract available.

31.

RF9, a potent and selective neuropeptide FF receptor antagonist, prevents opioid-induced tolerance associated with hyperalgesia.

Simonin F, Schmitt M, Laulin JP, Laboureyras E, Jhamandas JH, MacTavish D, Matifas A, Mollereau C, Laurent P, Parmentier M, Kieffer BL, Bourguignon JJ, Simonnet G.

Proc Natl Acad Sci U S A. 2006 Jan 10;103(2):466-71. Epub 2006 Jan 3. Erratum in: Proc Natl Acad Sci U S A. 2006 Oct 24;103(43):16058.

32.

Decreased oral self-administration of alcohol in kappa-opioid receptor knock-out mice.

Kovacs KM, Szakall I, O'Brien D, Wang R, Vinod KY, Saito M, Simonin F, Kieffer BL, Vadasz C.

Alcohol Clin Exp Res. 2005 May;29(5):730-8.

PMID:
15897716
33.

Identification of a novel family of G protein-coupled receptor associated sorting proteins.

Simonin F, Karcher P, Boeuf JJ, Matifas A, Kieffer BL.

J Neurochem. 2004 May;89(3):766-75.

34.

Structure-activity study of the ORL1 antagonist Ac-Arg-D-Cha-Qaa-D-Arg-D-p-ClPhe-NH2.

Van Cauwenberghe S, Simonin F, Cluzeau J, Becker JA, Lubell WD, Tourwé D.

J Med Chem. 2004 Mar 25;47(7):1864-7.

PMID:
15027881
35.

Antibody response and allogeneic mixed lymphocyte reaction in mu-, delta-, and kappa-opioid receptor knockout mice.

Gaveriaux-Ruff C, Simonin F, Filliol D, Kieffer B.

J Neuroimmunol. 2004 Feb;147(1-2):121-2.

PMID:
14741441
36.

Differential involvement of the mu and kappa opioid receptors in spatial learning.

Jamot L, Matthes HW, Simonin F, Kieffer BL, Roder JC.

Genes Brain Behav. 2003 Apr;2(2):80-92.

37.

Enhanced humoral response in kappa-opioid receptor knockout mice.

Gavériaux-Ruff C, Simonin F, Filliol D, Kieffer BL.

J Neuroimmunol. 2003 Jan;134(1-2):72-81.

PMID:
12507774
38.

Probing opioid receptor interactions with azacycloalkane amino acids. Synthesis of a potent and selective ORL1 antagonist.

Halab L, Becker JA, Darula Z, Tourwé D, Kieffer BL, Simonin F, Lubell WD.

J Med Chem. 2002 Nov 21;45(24):5353-7.

PMID:
12431062
39.

Two faces for an opioid peptide--and more receptors for pain research.

Simonin F, Kieffer BL.

Nat Neurosci. 2002 Mar;5(3):185-6. No abstract available.

PMID:
11865303
40.

Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors.

Ghozland S, Matthes HW, Simonin F, Filliol D, Kieffer BL, Maldonado R.

J Neurosci. 2002 Feb 1;22(3):1146-54.

41.

Autoradiographic mapping of the opioid receptor-like 1 (ORL1) receptor in the brains of mu-, delta- or kappa-opioid receptor knockout mice.

Slowe SJ, Clarke S, Lena I, Goody RJ, Lattanzi R, Negri L, Simonin F, Matthes HW, Filliol D, Kieffer BL, Kitchen I.

Neuroscience. 2001;106(3):469-80.

PMID:
11591451
42.

Immunosuppression by delta-opioid antagonist naltrindole: delta- and triple mu/delta/kappa-opioid receptor knockout mice reveal a nonopioid activity.

Gavériaux-Ruff C, Filliol D, Simonin F, Matthes HW, Kieffer BL.

J Pharmacol Exp Ther. 2001 Sep;298(3):1193-8.

PMID:
11504820
43.

Analysis of [3H]bremazocine binding in single and combinatorial opioid receptor knockout mice.

Simonin F, Slowe S, Becker JA, Matthes HW, Filliol D, Chluba J, Kitchen I, Kieffer BL.

Eur J Pharmacol. 2001 Mar 2;414(2-3):189-95.

PMID:
11239918
44.

In vitro pharmacological profile of peptide III-BTD: a novel ligand for nociceptin/orphanin FQ and opioid receptors.

Bigoni R, Rizzi A, Rizzi D, Becker JA, Kieffer BL, Simonin F, Regoli D, Calo G.

Life Sci. 2000 Dec 1;68(2):233-9.

PMID:
11191640
45.

Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses.

Filliol D, Ghozland S, Chluba J, Martin M, Matthes HW, Simonin F, Befort K, Gavériaux-Ruff C, Dierich A, LeMeur M, Valverde O, Maldonado R, Kieffer BL.

Nat Genet. 2000 Jun;25(2):195-200.

PMID:
10835636
46.

Ligands for kappa-opioid and ORL1 receptors identified from a conformationally constrained peptide combinatorial library.

Becker JA, Wallace A, Garzon A, Ingallinella P, Bianchi E, Cortese R, Simonin F, Kieffer BL, Pessi A.

J Biol Chem. 1999 Sep 24;274(39):27513-22. Erratum in: J Biol Chem 1999 Nov 12;274(46):33177.

47.

Quantitative autoradiography of mu-,delta- and kappa1 opioid receptors in kappa-opioid receptor knockout mice.

Slowe SJ, Simonin F, Kieffer B, Kitchen I.

Brain Res. 1999 Feb 13;818(2):335-45.

PMID:
10082819
48.

Dynorphin A as a potential endogenous ligand for four members of the opioid receptor gene family.

Zhang S, Tong Y, Tian M, Dehaven RN, Cortesburgos L, Mansson E, Simonin F, Kieffer B, Yu L.

J Pharmacol Exp Ther. 1998 Jul;286(1):136-41.

PMID:
9655852
49.
50.

Detection of opioid receptor mRNA by RT-PCR reveals alternative splicing for the delta- and kappa-opioid receptors.

Gavériaux-Ruff C, Peluso J, Befort K, Simonin F, Zilliox C, Kieffer BL.

Brain Res Mol Brain Res. 1997 Sep;48(2):298-304.

PMID:
9332727

Supplemental Content

Loading ...
Support Center